Tern Plc raises £642,486 through underwritten Open Offer

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things technology businesses, announces the result of its underwritten Open Offer to Qualifying Shareholders which was announced on 14 July 2025 and closed for acceptances, in accordance with its terms, on 28 July 2025.

The Company announces that valid acceptances have been received from Qualifying Shareholders for a total of 27,704,433 Open Offer Shares, representing a take-up of approximately 43% of the 64,248,646 Open Offer Shares available.  All Qualifying Shareholders who have validly applied for Open Offer Shares will therefore receive their full Basic Entitlement. Applications for Open Offer Shares from Qualifying Shareholders under the Excess Application Facility will also be satisfied in full.

The Open Offer Shares not taken up by Qualifying Shareholders, being 36,544,213 Open Offer Shares (equivalent to 5.69% of the Company’s Enlarged Share Capital), are to be subscribed for by the Underwriter (being CMC Markets UK plc), pursuant to the terms of the Underwriting Agreement, as described in the Circular and in the announcement of 14 July 2025.

Accordingly, subject to Admission becoming effective, 64,248,646 Open Offer Shares will be issued in connection with the Open Offer, raising approximately £642,486 (before expenses) for the Company at the Issue Price of 1.00 pence per Open Offer Share.

PDMR participation in the Open Offer

The following persons discharging managerial responsibilities (“PDMRs“) of the Company have participated in the Open Offer, as follows:

PDMRNumber of Existing Ordinary Shares heldNumber of Open Offer Shares subscribed forNumber of Ordinary Shares held on Admission% of the Enlarged Share Capital on Admission
Iain Ross (Non-Executive Director)1,210,000134,4441,344,4440.21%
Al Sisto (non-board CEO)12,158,147170,53412,328,6811.92%

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation (2014/596/EU) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 and as modified by or under the European Union (Withdrawal) Act 2018 or other domestic law, provide further detail.

Admission and dealings

The Open Offer Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with each other and with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of Admission. Application has been made to the London Stock Exchange for the Open Offer Shares to be admitted to trading on AIM. Dealings in the Open Offer Shares and Admission are expected to take place on or around 8.00 a.m. on 31 July 2025.

Total voting rights

In accordance with the Financial Conduct Authority’s Disclosure, Guidance and Transparency Rules, the Company confirms that following Admission, the Company’s enlarged issued ordinary share capital will comprise 642,486,466 Ordinary Shares. The Company does not hold any shares in Treasury.  Therefore, from Admission, the total number of voting rights in the Company will be 642,486,466 and this figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in Tern Plc, under the Disclosure Guidance and Transparency Rules.

Defined terms used in this announcement have the same meaning as those set out in the Company’s announcement released on 14 July 2025.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search